Lilly(US:LLY) Zhi Tong Cai Jing·2025-11-10 01:39Core Insights - Insilico Medicine has entered into a strategic drug development collaboration with Eli Lilly, leveraging its AI-driven Pharma.AI platform to accelerate the discovery and development of innovative therapies [1][2] Group 1: Collaboration Details - The partnership will utilize Insilico's Pharma.AI platform for generating, designing, and optimizing candidate compounds based on mutually agreed innovative targets [1] - Insilico is entitled to receive over $100 million from this collaboration, which includes upfront payments, milestone payments, and tiered royalties from future drug commercialization [1] Group 2: Background and Significance - This collaboration marks an upgrade in the relationship between Insilico and Eli Lilly, following a software licensing agreement established earlier in 2023 [1] - Insilico's CEO, Alex Zhavoronkov, emphasized the recognition of Insilico's AI-driven drug development capabilities and the importance of this partnership in meeting global patient needs [2] Group 3: Efficiency in Drug Development - Insilico has significantly improved early drug development efficiency, reducing the traditional drug discovery timeline of 3 to 6 years to an average of 12 to 18 months for candidate nomination [2] - From 2021 to 2024, Insilico has nominated 20 preclinical candidate compounds, with each project requiring the synthesis and testing of only 60 to 200 molecules, enhancing speed and resource utilization [2]